EU PHARMACEUTICALS CJC-1295 DAC
EU PHARMACEUTICALS CJC-1295 DAC(2MG/2ML VIAL)
CJC-1295 DAC has shown some amazing results as a growth hormone releasing hormone (GHRH) analog. Not only has CJC-1295 shown the ability to increase growth hormone and IGF-I secretion and its benefits, but it has been able to do so in very large amounts. Recent research studies have shown that CJC - 1295 stimulates GH and IGF-1 Secretion, and will keep a steady increase of HGH and IGF-1 with no increase in prolactin, leading to intense fat loss, and increases protein synthesis.
CJC-1295 DAC is a long acting Growth Hormone Releasing Hormone, which causes the anterior pituitary to release more growth hormone. GHRH is released in pulses in the body, which alternate with corresponding pulses of somatostatin (growth-hormone inhibiting-hormone). Clinical Research was first conducted for CJC-1295 during the mid-2000s. The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous hgH are presumed to increase lipolysis (fat loss). The clinical research was ultimately successful for most research subjects. Ghrelin, released from the gut, which circulates and acts as a hunger hormone, has synergistic activity in the body with GHRH and also suppresses somatostatin to make way for the GHRH pulse. Studies shows that combining a GHRP-6 with CJC 1295 DAC, significantly increase the release of GH and IGF-1 production without an increase in prolactin. An example of a GHRP (GH Releasing Peptide) is Hexarelin or GHRP-2. CJC 1295 DAC is a exceptionally designed peptide and is known for being the finest of the hGH secretogues. The DAC (Drug Affinity Complex) portion increases the half-life by binding with serum albumin and protects the CJC-1295 DAC peptide from degradation. This was formed when a lysine link was bounded to DACs to a reactive chemical called maleimidoproprionic acid (MPA).
CJC-1295 DAC vs. CJC-1295 No DAC
CJC-1295 DAC and CJC-1295 (also known as Modified GRF 1-29) are both Growth Hormone Releasing Hormones (GHRH). Their action in the human body is identical but the difference between the two peptides are the span of the half-life. Modified GRF 1-29 and Sermorelin have a very short acting half-life of about 30 minutes, while CJC-1295 DAC has a half-life that can last up to approximately 8 days.
CJC1295 has a very long half-life and therefore it has no dietary restrictions or specific times that you. Because of its long half-life it has long-term benefits on your body’s basal GH levels. CJC1295 is a 30 amino acid peptide hormone where synthetic growth hormone contains a 191 amino acid chain. It attaches itself to the albumim receptor and this increases its half-life oppose to the normal growth hormone releasing hormones.
2000mcg per vial
1ml of water depending on the brand you use.
1000mcg (1mg) twice a week or 2000mcg (2mg) once a week. Dose per injection: 2mg or 1mg x 2 Injections per vial: 1 x 2mg dosages or 2 x 1mg dosages per week. Amount to Inject: If you have used 1ml of water for mixing then a 2mg dosage = 1ml (or 100 units on Insulin Syringe). If you want to inject 1mg twice a week and you have used 1ml of water then a 1mg dosage = 0.5ml (or 50 units).
This product was initially developed for AIDS patients that were obese. It increases muscle mass and decrease body fat. Increase lean muscle mass. Decrease body fat percentage. Increase growth hormone secretion of the pituitary gland.
- Because of its long acting properties this product works best in conjunction with short acting growth hormone releasing hormones like GHRP-2 and GHRP-6 to take advantage of the short-term GH pulse created after a CJC1295 injection.
- Intramuscular and subcutaneous routes lead to different onset times but roughly similar peaks and declines.